According to ClinicalTrials.gov, the study is expected to have overall survival data available in September 2013.
"How about $PTN? Can it get a place in your high-risk high return biotechs?"
(PTN) is cheap but too risky. Intranasal bremelanotide for erectile dysfunction blew up because the drug caused high blood pressure. Now, Palatin is testing an injectable version of bremelanotide for men with ED and women with female sexual dysfunction. The company says the new version of the drug is safer, but an injectable ED drug? That seems like a commercial flop in the making.
Traders and technicians may see something promising in the Palatin chart, but I see a company that was forced into a 1-for-10 reverse stock split in September 2010. The stock is down another 21% since the reverse split. That's not a comforting sign.
Richard H. emails,
"Why didn't you include Sangamo Biosciences
(SGMO - Get Report) in your list? To me their pipeline is farther advanced then those listed and it is also already seeing some revenue from Dow and Sigma-Aldrich."
Sangamo was considered but didn't make the "cheap" cut owing to a market value north of $300 million.
Why $300 million? I had to draw a line somewhere and it seemed reasonable.
While not on my list, Sangamo is definitely a biotech stock to follow in the second half of this year as the company readies release of data from a very important phase IIb study of its drug SB-509 in diabetic neuropathy. SB-509 is an engineered protein, or "zinc finger" designed to turn genes on or off. In this case, SB-509 is supposed to switch on a gene to regenerate nerve growth.
Sangamo's zinc-finger drug technology is unproven in humans and previously reported data from earlier studies of SB-509 in diabetic neuropathy have produced mixed results. The stock may not be cheap (by my subjective definition) but it is risky and does have the potential to soar if the phase IIb results are positive.
Don G. writes,
"Every article you write involving Apricus Biosciences
(APRI - Get Report) gives off the impression that you think Apricus is destined for failure. With that said, there is a well-respected analyst at Dawson James who has a price target at $8.25 for Apricus. You two seem to be on opposite sides of the spectrum when it comes to analyzing Apricus. Do you think Vitaros will be as big of a hit in Europe as Apricus is making it out to be, and do you see Apricus ever being able to reach the $8.25 price target that Wasserman at Dawson James put on it?"
You're right, I believe Apricus is destined for failure. Vitaros, a rub-on cream, has little chance in an erectile dysfunction market that will soon be dominated by generic versions of
Viagra. Apricus' management team has a bad habit of making promises and exaggerated claims that don't come true.
Scott S. asks,
"Thanks for your coverage of Vertex Pharmaceuticals
(VRTX - Get Report). What is the status with European approval of Incivek?"
Johnson & Johnson
(Vertex's European marketing partner and in charge of Incivek's approval there) has guided investors to an approval in the second half of the year. Unofficially, European approval (or an approval recommendation) is expected in July or August.
Have a happy Fourth of July.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to: